|
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) |
28/12/2018 |
CIM |
|
CIMAvax-EGF in patients at high risk of lung cancer |
22/10/2020 |
CIM |
|
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
01/10/2020 |
CIM |
|
NeuroEPO-Ataxia-Adults-Phase III |
19/11/2020 |
CIM |
|
Phyisician Led CIMAvax-EGF lung biomarkers |
11/03/2021 |
CIM |
|
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
|
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
18/06/2021 |
CIM |
|
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX |
21/05/2021 |
CIM |
|
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
22/05/2021 |
CIM |
|
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
18/06/2021 |
CIM |
|
Itolizumab-Plasmapheresis in patients with COVID-19 |
30/06/2021 |
CIM |
|
VSSPs in renal carcinoma. |
21/06/2023 |
CIM |
|
Nimotuzumab in COVID-19 |
21/05/2021 |
CIM |
|
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
20/10/2021 |
CIM |
|
NeuroEPO in mild-moderate Alzheimer's disease |
20/09/2022 |
CIM |
|
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
22/09/2022 |
CIM |
|
Her1 vaccine in metastatic colon and prostate cancer |
16/08/2023 |
CIM |
|
iorEPOCIM-Stroke-Phase I |
2012-09-17 |
CIMAB |
|
Nimotuzumab for the treatment of high grade of malignancy tumors |
2013-02-01 |
CIMAB |
|
NeuroEPO-Stroke. Phase I-II |
11/09/2014 |
CIMAB |
